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We have identified a novel function for a member of the transient receptor potential (TRP) protein
super-family, TRPM2, in prostate cancer cell proliferation. TRPM2 encodes a non-selective cation-
permeable ion channel. We found that selectively knocking down TRPM2 with the small
interfering RNA technique inhibited the growth of prostate cancer cells but not of non-cancerous
cells. The subcellular localization of this protein is also remarkably different between cancerous
and non-cancerous cells. In BPH-1 (benign), TRPM2 protein is homogenously located near the
plasma membrane and in the cytoplasm, whereas in the cancerous cells (PC-3 and DU-145), a
significant amount of the TRPM2 protein is located in the nuclei in a clustered pattern.
Furthermore, we have found that TRPM2 inhibited nuclear ADP-ribosylation in prostate cancer
cells. However, TRPM2 knockdown-induced inhibition of proliferation is independent of the
activity of poly(ADP-ribose) polymerases. We conclude that TRPM2 is essential for prostate cancer
cell proliferation and may be a potential target for the selective treatment of prostate cancer.
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Introduction
Prostate cancer is the second most prevalent cancer
among men over 50 years of age, with nearly 30000 men
dying from the disease each year in the United States.
Although many theories have been proposed and
investigated, the exact mechanism leading to develop-
ment and progression of prostate cancer remains
unknown. However, recent reports suggest that transient
receptor potential (TRPs) ion channel super-families
have a significant role in regulating calcium homeostasis
during prostate carcinogenesis.
1 The function of TRPM2
in cancer cells has recently been investigated.
2,3 Using a
cDNA array technique, significantly increased TRPM2
mRNA expression has been observed in prostate cancer
tissues and cell lines in comparison with normal prostate
tissues (http:/ /www.ncbi.nlm.nih.gov/projects/geo/gds).
TRPM2 is a member of the TRP protein super-family
of ion channels
4,5 that can be activated by ADP-ribose,
6
b-NAD,
7 TNFa,
8 or H2O2,
9 which results in an increase
in intracellular free calcium concentration ([Ca
2þ]i).
10
ADP-ribose is a breakdown product of NAD
þ, CD38,
cADP-ribose, and protein de-acetylation.
4,11 As a bifunc-
tional protein, TRPM2 protein contains a Nudix box in its
C-terminus,
12 which is a common motif of enzymes that
degrade nucleotide diphosphates in addition to serving as
a binding site for ADP-ribose.
13 This study is designed to
closely evaluate the role of TRPM2 in cell proliferation of
prostate cancer cells.
Materials and methods
Prostate cancer tissue sections
Small blocks of fresh prostate cancer tissue were obtained
during radial prostatectomy of prostate cancer patients
(mean age of 61 and Gleason score range of 6–8) at Tulane
Hospital and Clinics and the VA Hospital in New Orleans,
LA, USA (consent was approved by institution review
board for such studies). Tissues were snap-frozen in liquid
nitrogen after being carefully embedded in Tissue-Tek OCT
C o m p o u n d( J e dP e l l aI n c . ,R e d d i n g ,C A ,U S A ) .S a m p l e s
were microtomed into 6–7mm thick sections, mounted onto
clean uncoated glass slides, and stored at  801Cu n t i l
further processing.
Laser capture microdissection and RNA preparation
The sections were thawed at room temperature for 10s,
followed by normal hemotoxylin and eosin staining, air
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www.nature.com/pcandried, and subjected to laser capture microdissection
(LCM) using a PixCell II instrument and CapSure LCM
Caps (Arcturus Engineering, Mountain View, CA, USA).
Matched tumor cells and benign prostate epithelium
from LCM procured prostate from the same patient were
captured separately after identification, confirmation,
staging, and grading of the tissue area by a certified
pathologist. Laser captured cells from multiple serial
sections (roughly 2000–3000 pulses at spot diameter of
30mm and 25–35mW laser power) were pooled into a
500ml nuclease-free Eppendorf tube containing 400mlo f
TRI Reagent (Molecular Research Centre Inc., Cincinnati,
OH, USA) mixed with RNA carrier, 1mlo f1 0 mgml
 1 of
GenEluteTM Linear PolyAcrylamide (Sigma, St Louis,
MO, USA). After recovery of the RNA pellet, a DNase
treatment step was performed for 2h at 371Cu s i n g
2 unit of RQ1 RNase-free Dnase (Promega Corp., Madison,
WI, USA), followed by re-extraction and precipitation. The
RNA yield and integrity was determined using Agilent
2100 bioanalyzer (Agilent Technologies, Palo Alto, CA,
USA) with RNA LabChip (Ambion Inc., Austin, TX, USA).
Only RNA samples with distinguished bands of 28S and
18S and without multiple RNA degradation bands were
subjected to further analysis.
Cell culture
The human prostate epithelial cell line BPH-1 was a gift
from Dr Stuart W Hayward and Dr R Dahia of the
University of San Francisco. Other prostate cell lines,
including RWPE-1, PC-3, DU-145, and LNCaP were
purchased from ATCC (Manassas, VA, USA). For
comparison purposes, human cavernosal smooth muscle
cells routinely grown as primary culture in our labora-
tory and maintained in DMEM media containing 10%
heat inactivated fetal bovine serum were used as controls
for these studies. BPH-1, PC-3, DU-145, and LNCaP cells
were grown in RPMI-1640 medium containing 5% fetal
bovine serum. Normal epithelial RWPE-1 cells were
grown in kerationcyte-SFM medium containing
5ngml
 1 epidermal growth factor and 50mgml
 1 bovine
pituitary extract (Invitrogen Corp., Carlsbad, CA, USA).
All cells were cultured in a humidified incubator with
5% CO2 and 95% air at 371C.
Cell proliferation analysis
Proliferation was assessed using a WST-8 assay accord-
ing to manufacturer’s instructions. Briefly, 10mlo f
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disul-
phonyl)-2H-etrazolium (WST-8) was added to each well
at the end of treatment and incubated for one additional
hour. Optical density values were read by an ELISA plate
reader at wavelengths of 450 and 650nm. Results were
calculated as percentage of control. For the PARP activity
experiment, PC-3 cells were seeded in a 96-well plate at a
density of approximately 10
3 cells per well, in triplicate.
The following day, the cells were treated with the PARP
inhibitor NU1025 at concentrations ranging from 0.2 to
2m M for 24 and 72h.
Quantitative real-time PCR and RT–PCR
For quantitative real-time PCR, the primers of TRPM2
were forward: 50-CCATCCGTGACCTTCTCATT-30 and
reverse: 50-CTCTGAGCCCAGATGATTCC-30 (reverse).
The primers of b-actin used for real-time PCR were
forward: 50-GGCACCCAGCACAATGAAG-30 and reve-
rse: 50-GCCGATCCACACGGAGTACT 30 (reverse). SYBR
Green PCR master mix (Applied Biosystems, Warring-
ton, UK) was used to develop the real-time PCR in a
thermal cycler (GeneAmp 5700, Applied Biosystems). A
validation experiment was carried out to check whether
the efficiencies of all target and reference primers were
approximately equal.
For RT–PCR, RNA was extracted from prostate epithe-
lial cell lines and cancer cell lines using TRI-REAGENT
(Molecular Research Center Inc.). A 2mgs a m p l eo ft o t a l
RNA from each cell line was incubated with 1 unit of
RNase-free DNase for 10min at 371C and then at 651Cf o r
another 10min. Random primers (1mg) were then added
and the tube was kept at 701Cf o r5 m i n .S u b s e q u e n t l y ,
5ml of Moloney murine leukemia virus reverse transcrip-
tase reaction buffer (5 ), 1mlo f1 0 m M PCR nucleotide
mix, 25 units of rRNasin ribonuclease inhibitor, and 200
units of Moloney murine leukemia virus reverse tran-
scriptase were added to the tube and incubated at 371C
for 1h. All reagents were purchased from Promega Co.
The cDNA product (2ml) was mixed with 1.5 units
TaKaRa Taq, 2.5 ml1 0   PCR buffer, 2ml 2.5mM dNTP
mixture (TaKaRa Shuzo Co., Otsu, Japan), and 100pM of
each primer, with DEPC water added for a final volume of
25ml. The primers for TRPM2 were forward: 50-ATGCTA
CCTCGGAAGCTGAA-30 and reverse: 50-TTCTGGAGGA
GGGTCTTGTG-30; for TRPC3—forward: 50-CAAGTACC
CTCCAACCCTCA-30 and reverse: 50-CTGGCTGCTAG
ATCCCAGAA-30; for TRPV5—forward: 50-CGCTGTTGT
GAACCAGAATG-30 and reverse: 50-GCTGGAGGATG
AGgatgtgt-30; for GAPDH—forward: 50-TCAACGGATTT
GGTCGTATTGGG-30 and reverse: 50-TGATTTTGGAGG
GATCTCGC-30. The amplification protocol for PCR was
set as follows: 941Cf o r4 m i n ,f o l l o w e db y3 0c y c l e so f
amplification steps (941Cf o r2m i n ,6 01C for 30s, 721Cf o r
40s), and the final extension at 721Cf o r8 m i n .P C R
products were analyzed using agarose gel (1.5%) electro-
phoresis and visualized under UV light after staining with
ethidium bromide (1mgml
 1).
Western blot analysis
For nuclear protein extraction, nuclei were isolated from
both prostate cancer cell lines (PC-3 and DU-145) and
non-cancerous cell lines (BPH and RWPE-1) using
CelLytic NucLEAR Extraction kit (Sigma-Aldrich Inc.).
The nuclei were lysed and extracted by centrifugation at
13000g for 5min. The supernatant was collected and
protein concentrations were determined using BCA
reagent (PIERCE Chemical Co., Rockford, IL, USA). For
western blot analysis, an equal amount of protein (50mg)
from each cell extract was separated in SDS–PAGE gels
(Bio-Rad Laboratories, Hercules, CA, USA). The proteins
were transferred electrophoretically to a 0.2mm nitrocel-
lulose membrane. Non-fat dry milk (5%) in PBS contain-
ing 0.1% Tween 20 (PBS-T) was used as a blocking agent
for 1h at room temperature. The membrane was then
treated with 1:300 dilution of TRPM2 primary antibody
(Bethyl Laboratories Inc., Montgomery, TX, USA) at
41C overnight, rinsed briefly with PBS-T twice, and
incubated with HRP-conjugated secondary antibody
(dilution 1:2000 in PBS-T) for 1h at room temperature
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ECL western blot detection reagent kit (Amersham
Pharmacia Biotech, Piscataway, NJ, USA).
Immunofluorescent confocal microscopy
Cells were placed on chamber slides for 1 day to allow for
attachment. Cells were then subsequently washed three
times with PBS, fixed with methanol at  201C for 10min,
and permeabilized in 0.5% Triton X-100 in PBS for 5min.
After treatment with 20% goat serum for 10min, cells were
incubated with primary antibody (rabbit anti-TRPM2, 1:50,
Bethyl Laboratories Inc.) for 60min at room temperature,
which was followed by secondary antibody (goat anti-
rabbit IgG FITC conjugated, 1:200, Bethyl Laboratories
Inc.) for 30min in darkness. Propidium iodide (Abcam
Inc., Cambridge, MA, USA) was used for nuclear staining.
Confocal microscopy was performed using a Leica TCS
SP2 confocal microscope equipped with five lasers,
including Argon 488nm and HeNe 543nm (Leica Micro-
systems, Exton, PA, USA).
Small interfering RNA assay
Cells were cultured on 96-well microplates until B30%
confluence and then transfected with 40nM of either
small interfering RNA (siRNA) specific to TRPM2
(50-AUAGAUCAGGAACUCCGUCUC-30) or scrambled
siRNA (Integrated DNATechnology, Coralville, IA, USA)
using Lipofectamine 2000 transfection reagent (Invitro-
gen) according to the manufacturer’s instructions. Cell
growth was monitored by a WST-8 cell counting kit
(Alexis Biochemicals Corp., San Diego, CA, USA).
Statistical analysis
All data are expressed as mean±standard deviation. For
statistical analysis, Student’s t-test was used to compare
the differences between control and treatment groups. A
probability value of Po0.05 is considered statistically
significant and denoted by asterisk marks in the figures.
Results
TRPM2 mRNA expression in cancerous vs benign tissue
The expression of TRPM2 mRNA was examined using
real-time PCR in cells isolated by laser capture micro-
dissection from tumor tissues isolated from prostate
cancer patients as compared with that from cells of the
benign tissues of the same subjects. Our qRT–PCR
analysis demonstrated selective high expression of
TRPM2 transcripts in 75% of LCM-procured malignant
cells in comparison to matched microdissected benign
cells of surgical specimens (Table 1). It is noteworthy that
TRPM2 expression does not correlate with age or
Gleason score. However, our results further emphasize
the need to confirm these observations in a large cohort
of prostate cancer patients.
TRPM2 mRNA expression in prostate cancer cell lines
RT–PCR analysis was performed to evaluate TRPM2
mRNA expression in prostate cancer cell lines (DU-145,
LNCaP, and PC-3). As shown in Figure 1, all three types
of cells yielded a clear PCR product band (293bp) of
TRPM2. These data suggest that these cell lines are
appropriate models for studying the mechanism of
TRPM2 underlying cancer progression.
Subcellular expression of TRPM2 in prostate cells
We examined the sub-cellular distribution of TRPM2 in
prostate cancer and non-cancerous prostate cell lines
using immunofluorescent confocal microscopy. As
shown in Figure 2a, TRPM2 proteins are located at the
plasma membrane and cytoplasm in BPH-1 cells.
However, in the prostate cancer cell lines (PC-3 and
DU-145), TRPM2 is also highly expressed in the nuclear
region in a clustered pattern. The expression of TRPM2
in RWPE-1 cells is very low in our experiment. To
confirm the predominant expression of TRPM2 in the
nuclei of prostate cancer cells, nuclear proteins from PC-3
and DU-145 cells were extracted and analyzed using
western blot analysis. Equal amounts of protein extracts
(50mg) from the different cell lines were used for western
blot analysis. As shown in Figure 2b, expression of
TRPM2 protein was detected in the nuclei of prostate
cancer cells (PC-3 and DU-145). In contrast, TRPM2 was
absent in the nuclei of benign (BPH-1) or normal prostate
epithelium cells (RWPE-1). These data confirm that
TRPM2 is expressed in the nuclei of prostate cancer
cells. Our western blot analysis also detected TRPM2
expression in the cytoplasm preparations in PC-3,
DU-145, and BPH-1 cells, but not in RWPE-1 cells. This
is consistent with the data in Figure 2a.
Involvement of TRPM2 in prostate cancer cell proliferation
To examine the role of TRPM2 in prostate cancer cell
proliferation, we conducted experiments to selectively
block the expression of TRPM2 mRNA by transfecting
Table 1 Quantitative real-time RT–PCR test of the abundance of
TRPM2 in prostate cancer tissues from patients
Patient’s
code
Age when
surgery
Gleason
score
TRPM2 level
(cancer/BPE)
#18 59 6 5.31
#24 58 6 17.63
#34 70 8 10.93
#39 54 6 3.53
#56 68 7 1.13
#65 64 6 4.08
#71 65 6 0.91
#82 53 7 0.62
Abbreviation: BPH, benign prostate epithelium.
Figure 1 RT–PCR analysis of TRPM2 mRNA expression in
prostate cancer cell lines. BPH, benign prostatic hyperplasia.
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Prostate Cancer and Prostatic DiseasessiRNA specifically targeting TRPM2 (siRNA-TRPM2) into
prostate cancer cells and non-cancerous prostate cells and
examining the effect of the siRNA on the proliferation of
these cells. As shown in Figure 3a, a significant inhibitory
effect on prostate cancer cell proliferation was observed in
siRNA-TRPM2-treated cells as compared with control cells
that were not transfected with siRNA or cells treated with
scrambled siRNA (Po0.05). In contrast, siRNA-TRPM2
had no inhibitory effect on RWPE-1 or BPH-1 cell
proliferation. These data suggest that knockdown of
TRPM2 does not inhibit cell growth in non-cancerous
prostate epithelial cells, but specifically inhibits growth of
prostate cancer cells.
The efficiency of the siRNA-TRPM2 in suppressing
TRPM2 expression was examined with the RT–PCR
method. Figure 3b shows that siRNA-TRPM2 success-
fully blocked the expression of TRPM2 mRNA in both
PC-3 and DU-145 cells. The expression of TRPM2 protein
was also inhibited by siRNA-TRPM2 treatment, as
shown in Figure 3c. Western blot analysis shows the
expression of TRPM2 protein was significantly reduced
in PC-3 cells treated with siRNA-TRPM2 when com-
pared with scrambled siRNA treatments. Pretreating
the primary antibody with a specific blocking peptide
completely prevented binding of the antibody to the
TRPM2 protein.
Effect of knockdown of TRPM2 on ADP-ribosylation in
prostate cancer cells
On the basis of the finding that TRPM2 is relocated in the
nucleus of prostate cancer cells and the fact that TRPM2
has ADP-ribose pyrophosphatase activity,
6,12 we hy-
pothesized that TRPM2 may decrease the level of poly
ADP-ribose in the nucleus of cancer cells by catalyzing
ADP-ribose to ribose 5-phosphate and AMP.
14 To test this
hypothesis, we transfected (Lipofectamine, Invitrogen)
siRNA-TRPM2 (40nM) into PC-3 and BPH-1 cells for 72h
to knock down the expression of TRPM2 specifically. We
then measured level of ADP-ribosylation in the cells with
fluorescent microscopy and ELISA.
As shown in Figure 4a, control PC-3 cells and PC-3
cells treated with scrambled siRNA presented low levels
of ADP-ribosylation, as indicated by only a few cells
being stained with the red fluorescent dye (anti-ADP-
ribose conjugated with Texas Red). Conversely, substan-
tial increases in the occurrence and intensity of red
fluorescence in stained PC-3 cells were observed in
siRNA-TRPM2-treated cells, suggesting that an increase
in ADP-ribosylation occurred even though the total
number of living cells was reduced significantly under
this condition. In Figure 4a, total cell number was less
after the treatment with siRNA-TRPM2 than the control
or scrambled siRNA; this is consistent with the experi-
mental result shown in Figure 3a.
An ELISA assay was used to evaluate the level of
ADP-ribosylation in PC-3 and BPH-1 cells (Figure 4b). In
general, the ADP-ribosylation was higher in PC-3 cells
than that in BPH-1 cells. After treatment with siRNA-
TRPM2 for 72h, an approximately threefold increase in
the ADP-ribosylation was measured in PC-3 cells,
whereas no observable difference was seen in BPH-1
cells. These data are consistent with our previous
observation that showed specific TRPM2 protein expres-
sion in the nuclei of prostate cancer cells and no such
expression in the nuclei of BPH-1 cells.
PARP-independent inhibition of ADP-ribosylation by
TRPM2 in prostate cancer cells
Poly ADP-ribosylation is a transient posttranslational
modification of nuclear proteins, mainly catalyzed by
poly ADP-ribose polymerases (PARPs). ADP-ribose in
the nucleus is converted into poly ADP-ribose by PARPs,
a process that has an important function in DNA repair
15
and cell replication.
16 Poly ADP-ribosylation also has a
role in G0–G1 transition during cell cycle progression.
17
Over-activation of PARP can cause cell necrosis because
of the depletion of cytoplasmic ATP.
18,19 To examine the
Figure 2 (a) Confocal microscopy showing the subcellular expres-
sion of TPRM2 protein in prostate cancer cell Lines (PC-3, DU-145),
benign cells (BPH-1), and normal prostate epithelial cell line
(RWPE-1). DU-145 is the 15th section of the z-series images (30
series). PC-3, BPH-1, and RWPE-1 are the 10th section of the z-series
images (30 series). Red is propidium iodide (PI) label of nuclei and
green is FITC fluorescence conjugated secondary antibody against
TRPM2 antibody. Single arrows indicate the nuclear location of
TRPM2 in cancer cells. Double arrow indicates plasma membrane
expression of TRPM2 in BPH-1 cells. All images are the overlays of
FITC and PI fluorescence. (b) Expression of TPRM2 proteins in both
the nuclei and the remainders (whole cell preparation excluding
nuclei) of prostate cancer cell lines (PC-3 and DU-145) and non-
cancerous prostate epithelium cell lines (BPH and RWPE-1).
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tion of prostate cancer cells, we used the PARP-1
inhibitor NU1025 (8-hydroxy-2-methylquinazoline-4-
(3H)one) to inhibit the activity of the major subtype of
PARPs, PARP-1,
20 in cells treated with siRNA-TRPM2.
Dose-dependent toxicity of NU1025 on PC-3 cell
proliferation starts at 200mM (Figure 4c). PC-3 cells were
seeded in a 96-well plate at B1000 cells per well in
triplicate. Then, cells were treated with 100mM of
NU1025 together with siRNA-TRPM2 or scrambled
siRNA for 4 days. NU1025 treatment did not affect cell
proliferation when it was applied alone; NU1025 co-
treatment did not rescue TRPM2-siRNA-mediated in-
hibition of cell proliferation (Figure 4d). These results
suggest that TRPM2 knockdown-induced inhibition
of proliferation is independent of the activity of poly
(ADP-ribose) polymerases.
Discussion
Previous studies have shown that TRPM2 channels are
expressed primarily in the plasma membrane and have a
key role in oxidative stress-induced cell death.
12 Our
results show a unique and previously unreported role for
the TRPM2 protein, facilitating or promoting cell
proliferation in cancer cells. The observation of a Ca
2þ
channel plays a non-Ca
2þ transport function is surpris-
ing, but not completely new. It has been reported that an
L-type voltage-gated Ca
2þ channel is proteolytically
cleaved to form a C-terminal fragment, which is
translocated into the nucleus and alters the endogenous
transcription of a wide variety of genes.
21 However, the
molecular mechanisms that mediate this change in
functionality in the TRPM2 protein between cancerous
and non-cancerous tissues remain elusive. The difference
in the subcellular locations of TRPM2 between cancerous
and non-cancerous prostate cells may explain the
switching of these two roles. In non-cancerous cells,
TRPM2 proteins are mainly located at the plasma
membrane where they mediate sodium and calcium
influx on oxidative stimulation. As a result, these cation
influxes may lead to membrane depolarization and
changes in calcium homeostasis that can lead to
programed cell death. In cancer cells, the role of TRPM2
as a plasma membrane ion channel is less important
because of the internalization and nuclear localization of
TRPM2. Abundant TRPM2 proteins are translocated into
the nucleus (Figure 2) where they may have an important
enzymatic function relating to cancer cell proliferation.
We anticipate this TRPM2 nuclear translocation is a more
general phenomenon as we also have observed it in other
types of cancer cells (data not shown).
It has been reported that two fragments (sense and
antisense transcriptions) of TRPM2 are specifically
expressed in cancer cells,
3 as our PCR and antibody
targeted the C-terminus (exons 30–32, exon 25, respec-
tively) it will be very interesting to see if the nuclear
expressed TRPM2 represent or include the TRPM2
fragment of the sense transcription. If so, the cancer-
specific transcription will create two functionally im-
portant fragment proteins—the antisense fragments
inhibit the normal Ca
2þ transport function of TRPM2
and the sense fragment conducts enzymatic function in
the nucleus simultaneously.
Zhang et al.
22 have suggested that TRPM2 activation
resulted in PARP cleavage and in a c t i v a t i o ni nh e m a t o p o i e -
tic cells through a mechanism involving [Ca
2þ]i elevation.
Our data show that knocking down TRPM2 increased
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Figure 3 Selective inhibitory effect of siRNA-TRPM2 on prostate cancer cell proliferation. (a) Cell proliferation monitored in cell lines PC-3,
DU-145, BPH-1, and RWPE-1 with WST-8 assay. The open square represents the data from untreated cells (control). The open triangle
represents data from cells treated with 40nM scrambled siRNA. The open circle represents the data from cells treated with 40nM siRNA-
TRPM2. N¼3 for all groups. Error bar represents the standard deviation. *Indicates Po0.05 between siRNA-TRPM2 treatment and the two
other groups. (b) RT–PCR showed that TRPM2 mRNA expression is inhibited by the siRNA-TRPM2 treatment in DU-145 and PC-3 2 days
after the siRNA transfection. The sizes of PCR products are 293bp and 234bp for TRPM2 and GAPDH, respectively. (c) Western blot shows
that TRPM2 protein expression is inhibited in PC-3 by 40nM siRNA-TRPM2 treatment for 72h. Repeated three times. siTRPM2: siRNA-
TRPM2.
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mechanism and also that direct blockade of PARP-1 activity
by NU1025 did not prevent siRNA-TRPM2-induced inhibi-
tion of prostate cancer cell proliferation (Figure 4d). These
data suggest the activity of PARP-1 may not have a crucial
role in siRNA-TRPM2-induced inhibition of cancer cell
growth. Therefore, TRPM2 may have an important function
in cell proliferation independent of the activity of PARPs in
prostate cancer cells.
Dual localization in the plasma membrane and endo-
plasmic reticulum has been observed for TRPM8 ion
channel in prostate cancer cells. TRPM8 is closely related
to TRPM2, with 42% homology.
23 TRPM8 is highly
expressed in endoplasmic reticulum membrane as an ion
channel in prostate cancer cells and has an essential role in
prostate cancer cell survival.
24,25 However, nuclear expres-
sion of this channel has not been seen in prostate cancer
cells as we have observed for TRPM2. Whether TRPM2
also functions as an endoplasmic reticulum calcium
channel in prostate cancer cells is currently unknown.
Our data strongly suggest that TRPM2 has a major
function in the nuclei of prostate cancer cells.
Intracellular [Ca
2þ] regulation has a crucial role in
tumorigenesis, including cell replication and apoptosis.
26
Nuclear expression of TRPM2 may also influence nuclear
Ca
2þ concentration [Ca
2þ]n. The nuclear envelope
comprises an inner membrane that abuts the nucleo-
plasm and an outer membrane that is continuous with
the endoplasmic reticulum. Anchored within this enve-
lope are the nuclear pore complexes and several
intracellular calcium store-regulating molecules that
have been reported to have a role in the regulation of
[Ca
2þ]n. For example, inositol 1,4,5-trisphosphate (IP3)
and inositol 1,3,4,5-tetrakisphosphate (IP4) binding sites
have been identified in the inner membrane of the
nuclear envelope.
27–29 IP3 and IP4 serve as signal
molecules for either Ca
2þ release (IP3) or sequestration
(IP4) in the nucleus.
30 Another example is, cADP-ribose,
an endogenous regulator of type 2 ryanodine receptors
that induces Ca
2þ release from nuclear stores.
31 More
detailed information concerning the nuclear location of
TRPM2 will be useful in advancing our knowledge of
this aspect of prostate cancer proliferation.
The mechanism of TRPM2 transmigration into the
nucleus is currently unknown. TRPM2 itself does not
contain a nuclear localization signaling sequence; there-
fore, a chaperone may be involved in TRPM2 transporta-
tion. A similar mechanism could also be present for
TRPM2 considering evidence that inositol 1,4,5-trispho-
sphate receptors (IP3R) can migrate into the nucleus and
IP3R directly binds to TRPC channels.
32,33
TRPM2 is expressed in many non-cancerous cells, such
as brain and peripheral blood cells.
7,8,34 Considering the
function of TRPM2 in these cells is to serve as a mediator
of oxidative-stress-induced calcium influx (i.e., the
channel is at plasma membrane) and thus apoptosis in
those tissues, inhibition of TRPM2 may be beneficial in
terms of continued survival.
35 Selectively suppressing
the expression of TRPM2 or blocking the transmigration
of these proteins into the nucleus may not harm non-
cancerous cells, but may selectively inhibit prostate
cancer growth. Therefore, TRPM2 may be a potential
target for the selective control of prostate cancer growth
and cell proliferation.
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*Indicates Po0.01 of Student’s t-test between the siRNA-TRPM2
treated and the control groups. (c) Dose-dependent toxic effect of
UN1025 on PC-3 cells. (d) PC-3 cell proliferation of under the
conditions of 40nM siRNA-TRPM2 treatment and co-treatment with
siRNA-TRPM2 and 100mM UN1025.
#Indicates Po0.05 of Student’s
t-test between the siRNA-TRPM2 or UN1025þsiRNA-TRPM2
treated and the control groups.
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